Literature DB >> 813923

Quantitative studies of the growth and rejection of allogeneic tumour cells in mouse cerebrospinal fluid. Elimination in the absence of H-2 differences.

P C Doherty, R M Zinkernagel.   

Abstract

Following intracerebral (i.c.) inoculation DBA/2 (H-2d) mastocytoma cells (P815) grow to concentrations of greater than 10,000/mul in cerebrospinal fluid (CSF) of H-2 compatible BALB/c mice, but are completely eliminated from 90% of such animals within 12 days. A similar pattern occurs in allogeneic C57BL (H-2b) and random-bred WEHI mice, whereas syngeneic DBA/2 mice die within 7 days from unrestricted tumour growth. Rejection in BALB/c mice is enhanced by prior exposure to the tumour, but is severely depressed by pretreatment with cyclophosphamide. Leucocytes responsible for eliminating the mastocytoma are apparently not active against sarcoma 180 cells injected simultaneously. Subsequent to intraperitoneal inoculation with mastocytoma cells both BALB/c and C57BL mice generate significant cytotoxic activity in spleen, as measured by an in vitro 51Cr release assay. Cytolysis is abrogated by prior incubation of spleen cells with AKR anti-O ascitic fluid and complement, but not by normal AKR ascitic fluid and complement. Following i.c. exposure, however, much lower levels of cytotoxic activity are found in spleen, though specifically sensitized lymphocytes are also present in lymph nodes of the cervical chain.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 813923      PMCID: PMC1538104     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  SOME METABOLIC EFFECTS EXERTED BY AZASERINE AND PURINE ANALOGS IN VIVO.

Authors:  A C SARTORELLI; H F UPCHURCH; A L BIEBER; B A BOOTH
Journal:  Cancer Res       Date:  1964-08       Impact factor: 12.701

2.  A transplantable mast-cell neoplasm in the mouse.

Authors:  T B DUNN; M POTTER
Journal:  J Natl Cancer Inst       Date:  1957-04       Impact factor: 13.506

3.  An improved assay for the infectivity of in influenza viruses.

Authors:  S FAZEKAS DE ST GROTH; D O WHITE
Journal:  J Hyg (Lond)       Date:  1958-03

4.  Specificity and development of cytotoxic thymus-derived lymphocytes in lymphocytic choriomeningitis.

Authors:  P C Doherty; R M Zinkernagel; I A Ramshaw
Journal:  J Immunol       Date:  1974-04       Impact factor: 5.422

Review 5.  The non-H-2 histocompatibility loci and their antigens.

Authors:  R J Graff; D W Bailey
Journal:  Transplant Rev       Date:  1973

Review 6.  Immunogenetic and biological aspects of in vitro lymphocyte allotransformation (MLR) in the mouse.

Authors:  H Festenstein
Journal:  Transplant Rev       Date:  1973

7.  Cell-mediated immunity to bacterial infection in the mouse. Thymus-derived cells as effectors of acquired resistance to Listeria monocytogenes.

Authors:  R V Blanden; R E Langman
Journal:  Scand J Immunol       Date:  1972       Impact factor: 3.487

8.  A method for obtaining cerebrospinal fluid from mice.

Authors:  R I Carp; A L Davidson; P A Merz
Journal:  Res Vet Sci       Date:  1971-09       Impact factor: 2.534

9.  Relationship between proliferative and effector phases of the mixed lymphocyte reaction and graft-vs-host reaction.

Authors:  M Howe; L Berman; L Cohen
Journal:  J Immunol       Date:  1973-10       Impact factor: 5.422

10.  Detection of a graft-versus-host reaction between mice compatible at the H-2 locus.

Authors:  M H Salaman; N Wedderburn; H Festenstein; B Huber
Journal:  Transplantation       Date:  1973-07       Impact factor: 4.939

View more
  2 in total

1.  Treatment of mice with polyinosinic-polycytidilic polyribonucleotide reduces T-cell involvement in a localized inflammatory response to vaccinia virus challenge.

Authors:  R Korngold; P C Doherty
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

2.  In vivo treatment with an appropriate anti-Thy-1.2 monoclonal antibody abrogates hybrid resistance to Thy-1.1+ virus-immune effector T cells.

Authors:  P C Doherty; J E Allan; W Allan
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.